Wolfgang Miesbach: Award-Winning Poster on Long-Term AAV Gene Therapy Outcomes in Hemophilia B
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Delighted that this poster by Ulrike Reiss was awarded the first poster prize at EAHAD 2026 in Dublin. ‘9‑year outcomes of scAAV2/8‑LP1‑hFIXco enriched for full AAV capsids in adults with severe haemophilia B (PO041)’.
The study builds on the pioneering UCL/St Jude AAV8 haemophilia B programme, comparing a new vector prep enriched for full AAV capsids (full:empty 1:3) with the original 1:10 preparation to see whether this strategy improves FIX expression or liver safety over the long term:
FIX activity rose in the higher‑dose cohort, confirming robust liver transduction, but levels gradually declined over time instead of remaining fully stable.
Rates and patterns of vector‑associated transaminitis were similar to the earlier 1:10 study, suggesting that full‑capsid enrichment alone does not mitigate this immunogenicity signal.
Across 9 years of follow‑up there were no FIX inhibitors, no thrombotic complications and no late liver toxicity, reinforcing the long‑term safety of systemic AAV‑mediated FIX gene transfer in this cohort.
Overall, there was no clear advantage of the 1:3 full‑capsid preparation in terms of reducing transaminitis, enhancing transduction, or stabilising FIX expression compared with the original vector batch.
For me, this award‑winning poster is a great example of how meticulous vector characterisation plus truly long‑term clinical follow‑up can refine our understanding of AAV biology and guide the next generation of safer, more durablegene therapies for haemophilia B”
Stay updated with Hemostasis Today.
-
Feb 11, 2026, 10:30Tagreed Alkaltham: The Challenges No One Talks About in Blood Bank Leadership
-
Feb 11, 2026, 10:26Bartosz Hudzik։ Targeting Cardiovascular Aging May Refine Treatment Strategies for CVD
-
Feb 11, 2026, 10:22Jan Geissler: Empowering Early-Career Hematologists Through EHA’s CRTH Program
-
Feb 11, 2026, 09:40Shamee Shastry: Donor Counsellor Training Program for Safe Blood Systems
-
Feb 11, 2026, 09:32Narek Veranyan: Similar Postoperative and Mid-Term Outcomes in Patients With SGA Undergoing TEVAR
-
Feb 11, 2026, 09:21Sophia Delicou: How Does Lifelong Transfusion Therapy Affect Everyday Life of Adults with Hemoglobinopathies
-
Feb 11, 2026, 09:13Tareq Abadl: Hematuria vs Hemoglobinuria vs Myoglobinuria
-
Feb 10, 2026, 16:52Understanding Risks Factors of Cancer-Associated Thrombosis – World Thrombosis Day
-
Feb 10, 2026, 16:50Sophia Delicou: Does Hepatic Dysfunction Truly Reflect Thrombotic Risk in Hemoglobinopathies?